{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:03:53Z","timestamp":1792692233901,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL141584"],"award-info":[{"award-number":["K23HL141584"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24HL103844"],"award-info":[{"award-number":["K24HL103844"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL007891"],"award-info":[{"award-number":["T32HL007891"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016421","name":"Cardiovascular Medical Research and Education Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004008","name":"National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.chest.2022.02.041","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T20:16:04Z","timestamp":1646252164000},"page":"436-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5565","authenticated-orcid":false,"given":"Breanne E.","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina H.","family":"Appleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude S.","family":"Moutchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen K.","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Akaya","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Urbanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold I.","family":"Palevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Kawut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Al-Naamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2022.02.041_bib1","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.chest.2022.02.041_bib2","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ (Online)"},{"issue":"25 Suppl","key":"10.1016\/j.chest.2022.02.041_bib3","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2022.02.041_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.chest.2020.07.088","article-title":"United States Pulmonary Hypertension Scientific Registry: baseline characteristics","volume":"159","author":"Badlam","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.02.041_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1513\/AnnalsATS.202006-612OC","article-title":"Obesity in pulmonary arterial hypertension the pulmonary hypertension association registry","volume":"18","author":"Min","year":"2021","journal-title":"Ann Am Thoracic Soc"},{"key":"10.1016\/j.chest.2022.02.041_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.11-3241","article-title":"Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a reveal registry analysis","volume":"144","author":"Poms","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201207-1266ED","article-title":"Evolving epidemiology of pulmonary arterial hypertension","volume":"186","author":"Thenappan","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.02.041_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.chest.2018.05.006","article-title":"Association between BMI and obesity with survival in pulmonary arterial hypertension","volume":"154","author":"Weatherald","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib56","first-page":"1","article-title":"Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.chest.2022.02.041_bib12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/CIRCULATIONAHA.106.663120","article-title":"Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation","volume":"115","author":"Hansmann","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2022.02.041_bib13","article-title":"Obesity is associated with pulmonary hypertension and modifies outcomes","volume":"9","author":"Frank","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.chest.2022.02.041_bib14","first-page":"505274","article-title":"Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms","volume":"2012","author":"Friedman","year":"2012","journal-title":"J\u00a0Obes"},{"key":"10.1016\/j.chest.2022.02.041_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2017.04.051","article-title":"Relation between obesity and survival in patients hospitalized for pulmonary arterial hypertension (from a nationwide inpatient sample database 2003 to 2011)","volume":"120","author":"Agarwal","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.chest.2022.02.041_bib16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.healun.2011.03.011","article-title":"Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials","volume":"30","author":"Benza","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.chest.2022.02.041_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/AC.69.6.1000010","article-title":"Survival advantages of excess body mass index in patients with idiopathic pulmonary arterial hypertension","volume":"69","author":"Hu","year":"2014","journal-title":"Acta Cardiologica"},{"key":"10.1016\/j.chest.2022.02.041_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.rmed.2012.10.019","article-title":"The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the \u201cobesity paradox.\u201d","volume":"107","author":"Zafrir","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2022.02.041_bib19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1086\/678510","article-title":"Obesity-related pulmonary arterial hypertension in rats correlates with increased circulating inflammatory cytokines and lipids and with oxidant damage in the arterial wall but not with hypoxia","volume":"4","author":"Irwin","year":"2014","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.chest.2022.02.041_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020952023","article-title":"Obesity, estrogens and adipose tissue dysfunction\u2014implications for pulmonary arterial hypertension","volume":"10","author":"Mair","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.chest.2022.02.041_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01524-2018","article-title":"Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension","volume":"53","author":"Mair","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2022.02.041_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pupt.2012.06.006","article-title":"Fat, fire and muscle\u2014the role of adiponectin in pulmonary vascular inflammation and remodeling","volume":"26","author":"Medoff","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.chest.2022.02.041_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22031435","article-title":"Adipokines and metabolic regulators in human and experimental pulmonary arterial hypertension","volume":"22","author":"Papathanasiou","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.chest.2022.02.041_bib24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/ijms20040912","article-title":"Pulmonary hypertension and obesity: focus on adiponectin","volume":"20","author":"Perrotta","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.chest.2022.02.041_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST Guideline and Expert Panel Report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1183\/09031936.00078207","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension","volume":"31","author":"Dupuis","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2022.02.041_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/jcmm.13026","article-title":"Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells","volume":"21","author":"Favre","year":"2017","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.chest.2022.02.041_bib28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.chest.2016.05.024","article-title":"Riociguat: mode of action and clinical development in pulmonary hypertension","volume":"151","author":"Ghofrani","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2022.02.041_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/diseases6020038","article-title":"Pulmonary arterial hypertension: pathophysiology and treatment","volume":"6","author":"Lan","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.chest.2022.02.041_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","volume":"32","author":"Wilkins","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2022.02.041_bib32","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2022.02.041_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2022.02.041_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2022.02.041_bib35","first-page":"2894","article-title":"Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2022.02.041_bib36","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil Use in Pulmonary Arterial Hypertension Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.chest.2022.02.041_bib37","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2022.02.041_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2022.02.041_bib39","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2022.02.041_bib40","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2022.02.041_bib41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2022.02.041_bib42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2022.02.041_bib43","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2022.02.041_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pupt.2011.10.002","article-title":"Safety and efficacy of sitaxsentan 50 and 100\u00a0mg in patients with pulmonary arterial hypertension","volume":"25","author":"Sandoval","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.chest.2022.02.041_bib45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"10.1016\/j.chest.2022.02.041_bib46","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2022.02.041_bib47","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.02.041_bib48","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/sim.8516","article-title":"Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: statistical recommendations for conduct and planning","volume":"39","author":"Riley","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.chest.2022.02.041_bib49","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Wolfgang","year":"2010","journal-title":"J\u00a0Stat Software"},{"issue":"4","key":"10.1016\/j.chest.2022.02.041_bib50","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00241-2019","article-title":"The obesity paradox in pulmonary arterial hypertension: the Scottish perspective","volume":"5","author":"McLean","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.chest.2022.02.041_bib51","doi-asserted-by":"crossref","unstructured":"Min J, Appleby DH, McClelland RL, et\u00a0al. Secular and regional trends among pulmonary arterial hypertension clinical trial participants [published online ahead of print December 22, 2021]. Ann Am Thorac Soc. https:\/\/doi.org\/10.1513\/AnnalsATS.202110-1139OC.","DOI":"10.1513\/AnnalsATS.202110-1139OC"},{"key":"10.1016\/j.chest.2022.02.041_bib52","first-page":"198","article-title":"Severe pulmonary hypertension in postmenopausal obese women","volume":"11","author":"Taraseviciute","year":"2006","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.chest.2022.02.041_bib53","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.chest.2022.02.041_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046042","article-title":"Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice","volume":"7","author":"Stewart","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.chest.2022.02.041_bib55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ","volume":"36","author":"Burke","year":"2017","journal-title":"Stat Med"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222004081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222004081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T21:01:59Z","timestamp":1715115719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222004081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0012369222004081"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.02.041","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.02.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}